Hypofractionated accelerated radiotherapy in T1–3 N0 cancer of the larynx: A prospective cohort study with historical controls

Abstract

Aim

The goal of this prospective study was to assess the effectiveness of a hypofractionated accelerated regime in treatment of the larynx cancer.

Background

Multiple radiotherapy delivery regimes are used for treatment of the larynx cancer. Hypofractionated regimes could provide similar results with reduced use of radiotherapy facilities.

Material and methods

223 patients with squamous cell carcinoma of the upper or middle larynx have been treated with 63[[ce:hsp sp="0.25"/]]Gy delivered in 28 fractions of 2.25[[ce:hsp sp="0.25"/]]Gy during 38 days, 5 fractions per week. The study endpoints were overall survival, progression-free survival, early and late treatment toxicity. Standard and accelerated radiotherapy groups from the study published by Hliniak et al.[[ce:cross-ref id="crf0065" refid="bib0275"]]²⁰ served as controls.

Results

Five-year actuarial overall survival was 87.5% in the study group, 84.5% in the control group receiving accelerated radiotherapy (33 fractions of 2.0[[ce:hsp sp="0.25"/]]Gy, 6 fractions per week) and 86.2% in the control group (33 fractions of 2.0[[ce:hsp sp="0.25"/]]Gy, 5 fractions per week). Five-year progression-free survival was 73.6%, 77.2% and 66.2%, respectively. Overall, treatment toxicity and complication rates did not differ between the study group and the control groups.

Conclusions

The hypofractionated accelerated radiotherapy protocol using 5 fractions per week reduced the use of radiotherapy facilities. There was no significant difference in overall survival and progression-free survival between the study and control groups treated with accelerated or standard radiotherapy.